Streptococcus pneumoniae type 23f capsular polysaccharide antigen is a vaccine that contains highly purified capsular polysaccharides from the invasive pneumococcal type 23f of Streptococcus pneumoniae. It is an active immunization... It is an active immunization for intramuscular or subcutaneous injection against pneumococcal disease such as pneumococcal pneumonia and pneumococcal bacteremia.
- First approval
- Canada, 2005 · United States, 1983 · European Union, 2021
- Also known as
- pneumococcal capsular polysaccharide type 23F vaccine · Pneumococcal polysaccharide serotype 23F
- Brand names
Resolves to
Compound
Clinical / RWD
What you can answer from here — as of April 02, 2025
Which other approved drugs treat the same conditions as Streptococcus pneumoniae type 23f capsular polysaccharide antigen, and which companies have late-stage candidates in those indications?
Create a free account or log in to explore the full data card.
Create Account